In colorectal and breast cancers, overexpression of FABP4 and FABP5 has been correlated with recurrence risk and chemoresistance[76,110,189–191], suggesting their utility in identifying high-risk patients who may benefit from intensified adjuvant treatment or early postoperative monitoring strategies. This evidence concerns the gene FABP5 and breast carcinoma.